ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Lilly's Jaypirca significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
FDA approves Lilly's Foundayo , the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz plus Zepbound delivered superior efficacy for adults with psoriatic arthritis and obesity
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Zepbound , the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Lilly's Taltz and Zepbound used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
American Uranium Expands its Lo Herma ISR Uranium Project in Wyoming's Powder River Basin as Company Secures Strategically Located Uranium Mineral Rights and Stakes Additional Mining Claims
